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1. Introduction
Historically, asthma and COPD (chronic obstructive pulmonary disease) have been considered
separate and unique diseases with distinct characteristics. Classically, asthma has been
characterized by reversible airways obstruction and COPD by fixed, less reversible, or
irreversible airways obstruction. The definitions of asthma and COPD have undergone major
revisions recently and COPD, like asthma, has now been recognized as an inflammatory
disease of the airways [1, 2]. Even though asthma and COPD can be and are often appropriate‐
ly separated as clinical entities, there are times when they are clinically and physiologically
indistinguishable. As the American Thoracic Society guidelines for the diagnosis of COPD [3]
state, “the obstruction in many patients with COPD may include a significant reversible
component and that some patients with asthma may go on to develop irreversible airflow
obstruction indistinguishable from COPD.” This intersection of physiologic findings in asthma
and COPD has led to the development of the concept of what is now known as the overlap
syndrome of asthma and COPD [4]. As subcategories or phenotypes of asthma and COPD are
identified, the distinction between these two disorders is less well defined. Some of the
phenotypes exhibit very similar clinical, physiologic, and inflammatory profiles. The concept
of asthma and COPD viewed as separate disease states has evolved as definitions and
categorization of asthma and COPD change, and, as such, we are now encountering more
overlap among these two disorders than was previously recognized. So we now pose the
question: should asthma and COPD always be recognized and viewed as completely distinct
diseases or is there enough similarity to view them equivalently at times? In essence, does an
asthma-COPD overlap syndrome occur in some patients?
Multiple researchers have begun to view asthma as a diverse array of diseases distinguished
by unique phenotypes. In other words, perhaps asthma is not one single disease entity, but a
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collection of multiple subgroupings. Similarly, recent evaluations of COPD suggest that it is
also composed of multiple phenotypes [5, 6]. Furthermore, some of these COPD and asthma
subgroupings or phenotypes share similar clinical presentations and characteristics [7]. So,
from a clinical perspective, it may be appropriate to view these diseases as overlapping. Other
authors have extended these observations to speculate that asthma and COPD are part of the
same disease spectrum. Some offer the hypothesis that perhaps asthma turns into COPD or
perhaps asthma and COPD have similar pathogenetic origins in individuals with similar host
substrates and environmental exposures. Orie and coworkers [8] initiated a unified approach
over five decades ago when they postulated common processes and evolution of asthma and
COPD; they adopted the term chronic non-specific lung disease to include both disorders:
“asthma, chronic bronchitis and emphysema should be considered as different expressions of
one disease entity, in which both endogenous (host) and exogenous (environmental) factors
play a role in the pathogenesis.”
In addition, the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria
that were established in 2011 [9] began to characterize patients with COPD based not just on
their physiologic features, but also considered their clinical symptoms and risk for healthcare
utilization. The GOLD guidelines proposed categorization of individuals with COPD into four
distinct phenotypes based upon these characteristics (see Figure 1). Further, treatment
guidelines are based upon the patient’s categorization and phenotype.
New insights into asthma and COPD now recognize that there is much heterogeneity amongst
individual patients with asthma and with COPD. However, when comparing asthma and
COPD phenotypes, there appears to be cross-disease homogeneity amongst some of these
specific asthma and COPD phenotypes. Therefore, as asthma and COPD research continues,
the question remains: are asthma and COPD distinct and separate disease entities or are there
enough similarities between them to allow us to view them equivalently at times? In other
words, are asthma and COPD different disease states or is there significant overlap at the ends
of the spectrum? Furthermore, are they two distinct phenotypes of a similar disease process?
In this chapter, we will investigate the historical definitions and perspectives of these two
diseases and how they have been viewed and reported as distinct entities that are quite
different from each other. While explaining the historical definitions of these diseases, we will
highlight the differences and similarities in clinical manifestations, physiology, and airways
inflammation between COPD and asthma. We also describe asthma and COPD phenotypes
and discuss how separating asthma and COPD into multiple subcategories has paved the way
to recognize the heterogeneity of these processes. These phenotypes can often overlap across
disease states, especially those asthmatic patients that have a less-reversible form of airways
obstruction that presents like that of COPD. We will review airway remodeling and how it can
lead to chronic, more fixed obstruction in asthma. The concept of airways obstruction rever‐
sibility will be reviewed and the ambiguity and confusion of this nomenclature discussed.
Finally, we will discuss the overlap of treatment and therapies now used to treat both asthma
and COPD and where we are beginning to see success for the use of classical asthma treatments
for COPD and vice-versa.
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Abbreviations:mMRC-Modified Medical Research Council Dyspnea Scale, CAT-COPD Assessment Test questionnaire,
SABA=short acting beta-agonist, LABA-long acting beta-agonist, SAch-short acting anti-cholinergic, LAch-long acting
anti-cholinergic (also known as LAMA or long acting muscarinic antagonist), ICS-inhaled corticosteroid,
Figure 1. Adapted from [9]. A. Categorization of individuals according to the GOLD Guidelines [9] utilizes physiologic
impairment based upon the reduction in the FEV1, symptoms measured by either the COPD Assessment Test (CAT) or
the mMRC dyspnea scale, and risk measured by the number of exacerbations in the previous year. B. Use of the four
GOLD categories to define management strategies. Note the risk assessments are now made on the vertical axes with
airflow limitation and prior exacerbations taken into account, and the symptoms of the patient are also accounted for
on the horizontal axis. The symptoms assessments are identified and scored by patient reported items such as the
mMRC and CAT.
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1.1. Ambiguous nomenclature and the bronchodilator response controversy: should we stop
using the term reversible?
Although the historic definitions of asthma and COPD put an emphasis on the response to a
bronchodilator, there are some instances and examples where this delineation may not be as
useful. Although many asthmatics have normal lung function in between exacerbations or
symptoms and require bronchoprovocation testing to induce airflow limitation, the majority
of asthmatics experience relief of airflow limitation (AFL) when administered a bronchodilator
(BD) in a laboratory setting. Between 39 and 73% of individuals with COPD also will experience
significant improvement in AFL after receiving a BD [10]. In the Pulmonary Function Labo‐
ratory, an increase of 12% and at least 200 ml in either the FEV1 or FVC is usually defined as
bronchodilator responsive airflow limitation [11] that many clinicians consider “reversible.”
Reversibility is also frequently used in the definitions of asthma and COPD: asthma is
reversible and COPD is non-reversible airflow limitation; but in these definitions, reversible
does not refer to the response to a bronchodilator but to the ability of airflow to return to normal
or predicted levels in asthma and the inability to return to normal or predicted levels in COPD.
Thus, reversible refers to two very different concepts: response to a bronchodilator (in the PFT lab)
and normalization (in the definitions of COPD and asthma). This ambiguous use of the word
reversible has led many clinicians to diagnose asthma when a patient has a measured response
to bronchodilators in the PFT lab even when their lung function does not achieve predicted
levels. Similarly, an individual with airflow limitation that does not improve with broncho‐
dilators is often diagnosed with COPD and not asthma. Pulmonary physiology measured in
the PFT lab can assist with the diagnosis of COPD and asthma but is insufficient to diagnosis
either COPD or asthma.
Throughout this chapter, we will distinguish between bronchodilator responsivity and
normalization of spirometric lung function and clarify use of the ambiguous term, reversibility.
Bronchodilator responsivity will refer to improvement in either FEV1 or FVC by 12% and 200
cc after bronchodilator administration [12] and normalization will refer to a return to normal
or predicted values for the FEV1 and FVC either during intercurrent periods of pulmonary
disease activity or after bronchodilator use.
Thus, an individual with COPD will have non-normalizing lung function but could still have
a bronchodilator response and most individuals with asthma will have normalizing lung
function during periods of disease inactivity. Asthmatics with fixed airflow limitation have
lost the ability to normalize their lung function and are inseparable physiologically from
individuals with COPD.
In the December 2011 revision, the GOLD Guidelines [9] list several differences between
asthma and COPD and stress the importance of the concept of “reversible” (normalizing)
airflow obstruction. COPD is described as having onset in mid-life, slowly progressive
symptoms, and a history of tobacco smoking or exposure to other types of smoke, whereas
asthma begins early in life and symptoms vary widely from day to day. The definition of COPD
in the GOLD guidelines clearly “excludes asthma (‘reversible (normalizing) airflow limita‐
tion’)” and also states that the presence of a post-bronchodilator FEV1/FVC < 0.70 confirms the
presence of persistent (or non-normalizing) airflow limitation and thus of COPD. Once again,
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we see authors stress the importance of separating “reversible” from “non-reversible” airflow
limitation as helping in defining and distinguishing asthma and COPD. However, as Pelle‐
grino and colleagues [11] state, “The lack of a response to bronchodilator testing in a laboratory
does not preclude a clinical response to bronchodilator therapy.” Should we limit asthma
therapy to only those patients who have normalizable AFL after BD? This decision could
narrow a patient’s therapeutic options and exclude potentially beneficial medications.
Certainly for the majority of patients a reasonable classification of asthma and COPD can
be based on how airflow returns to predicted or normal levels after the administration of
a bronchodilator. But many asthmatics can have fixed or non-normalizing airflow limita‐
tion after  a  bronchodilator  is  administered in a  laboratory setting.  Some asthma pheno‐
types  have  significant  inflammation  and  airway  remodeling  that  leads  to  non-
normalizing AFL that does not respond to a bronchodilator. Therefore, it seems plausible
that some asthma patients indeed have fixed airflow obstruction and approaching them as
COPD patients may allow for more appropriate therapy. Using the normalization of AFL
after BD may be useful for defining the majority of asthma and COPD patients but airway
remodeling due to repetitive or persistent inflammation in asthmatics as they age and are
chronically  exposed  to  stimuli  can  account  for  the  fact  that  some  asthmatics  show  no
significant spirometric change after BD administration in a laboratory. Patients with either
asthma or COPD may respond to a BD so BD responsivity is neither sensitive nor specific
in distinguishing asthma and COPD.
2. Why is overlap between asthma and COPD important?
In  a  15  year  longitudinal  study  of  individuals  with  asthma,  Lange  and  colleagues  [13]
concluded that some asthmatics progress to fixed airways obstruction suggesting that this
asthmatic  subgroup may exhibit  non-normalizing lung function and be  more  similar  to
COPD. GOLD guidelines [9], NHLBI guidelines [14], and GINA [15] guidelines state that
asthma and COPD are underdiagnosed and misdiagnosed.  In addition,  these guidelines
attempt to distinguish asthma and COPD obviating recognition of potential overlap. Simply
put,  there  are  often  times  where  guideline-driven  therapy  for  COPD  and  asthma  may
preclude some patients from getting more tailored therapy. In the example of the asthma/
COPD overlap patient, guideline driven care may not optimize or individualize treatment
sufficiently. As listed in examples cited later in this chapter, many asthmatics with fixed or
non-normalizing AFL may benefit from treatments that are traditionally only considered
for patients with COPD. Thus, we feel it  is  imperative that a subgroup of patients with
asthma and COPD may benefit by approaching them therapeutically as having an “over‐
lap”  syndrome  of  asthma  and  COPD.  Furthermore,  classic  COPD  and  asthma  medica‐
tions  may  be  used  interchangeably  and  successfully  for  patients  with  overlapping
phenotypes. Therefore, viewing asthma and COPD similarly for some patients can lead to
more treatment options and possibly better outcomes.
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3. Clinical perplexity emanating from overlapping definitions and
ambiguous nomenclature
3.1. Defining these disorders has proven difficult
The recent movements to subcategorize asthma and COPD into distinctive phenotypes
underscores the imprecise and evolving definitions of these disorders; neither asthma nor
COPD are discrete diseases but rather syndromes that are defined or characterized by
multifactorial listings of historical, physical examination, radiographic, cellular, biochemical,
and physiologic features [9, 14, 15].
Historically, definitions have distinguished COPD with non-normalizing AFL in older adults
from asthma with normalizing AFL in children with atopy or pulmonary inflammation. Figure
2 summarizes the features of asthma and COPD that have been used historically to distinguish
these two disorders. Furthermore, as described in [4], “Asthma is recognized as an allergic
disease that develops in childhood, characterised physiologically by “reversible” (normaliz‐
ing) airflow obstruction, and has an episodic course with a generally favourable prognosis,
responding well to anti-inflammatory treatment. In contrast, COPD is typically caused by
tobacco smoking, develops in mid to later life and is characterised by incompletely“reversible”
(non-normalizing) airflow limitation that results in a progressive decline in lung function
leading to premature death.”
Further, since these disorders are syndromes, there is not a single gold standard diagnostic
test for either asthma or COPD. Bronchoprovocation testing has been advocated to comple‐
ment spirometric measurement of FEV1 and FVC before and after bronchodilators for the
diagnosis of asthma [14, 15]. For COPD, there is much debate over thresholds to define airflow
obstruction – that is with a fixed FEV1/FVC ratio less than 0.70 or an FEV1/FVC ratio less than
the lower limit of normal. Thus, it has been exceedingly difficult to define these disorders
precisely based upon physiologic testing.
Figure 2. Historical characteristics of asthma and COPD, adapted from [16].
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3.2. Revisiting the Dutch hypothesis and overlap syndrome proposals
Scientific and clinical evidence reinforces the overlap between COPD and asthma. The clinical
manifestations of these disorders, cough, breathlessness, and wheezing, may be identical. AFL
is present in both processes and BD responsiveness occurs frequently in either disorder. Cellular
and biochemical assessments reveal inflammation and immunological derangements. The
therapeutic pharmacologic armamentarium is very similar. Consequently, some investiga‐
tors have surmised that asthma and COPD may share common pathophysiologic origins. As
Bleecker suggests in [16], although the concepts of the Dutch hypothesis may be controver‐
sial, they have never been disproven and approaching these two diseases in a fashion that
recognizes the possibility of similarities could pave the way for new approaches for both COPD
and asthma.
Figure 3 illustrates the potential theoretical overlap among the obstructive lung diseases. The
need to recognize overlap amongst asthma and COPD was highlighted by Gibson and Simpson
[4] as the historical definitions of asthma and COPD are “limited because they do not fully depict
the spectrum of obstructive airway disease that is seen in clinical practice. In particular, now
that accelerated decline in lung function is recognized to occur in asthma, especially in those
with asthma who smoke and COPD is increasingly considered to be a treatment-responsive
disease, there is a need to re-evaluate the concept of asthma and COPD as separate condi‐
tions, and to consider situations when they may coexist, or when one condition may evolve into
the other.”
Figure 3. Overlapping of Obstructive Lung Diseases, reproduced from [3]. This non-proportional Venn diagram shows
subsets of patients with chronic bronchitis, COPD, emphysema, and asthma and their intersection with airflow ob‐
struction or airflow limitation (AFL) and each other. Patients with asthma whose airflow obstruction is reversible (nor‐
malizing) (subset 9), are not considered to have COPD. In many cases it is virtually impossible to differentiate patients
with asthma whose airflow obstruction does not remit completely from persons with chronic bronchitis or COPD who
have partially reversible (normalizing) airflow obstruction with airway hyperreactivity. Thus, some patients with unre‐
mitting asthma are classified as having COPD as shown by subsets 6, 7 and 8. Emphysema with AFL and chronic bron‐
chitis with AFL comprise COPD patients, and are depicted in the darker circles labeled as subsets 3 and 4. Chronic
bronchitis and emphysema with airflow obstruction often occur together as seen in subset 5, and some patients may
have asthma associated with these two disorders as in subset 8. Individuals with asthma exposed to chronic irritation,
as from cigarette smoke, may develop chronic productive cough, a feature of chronic bronchitis shown in subset 6.
Such patients are often referred to in the United States as having asthmatic bronchitis or the asthmatic form of COPD.
Persons with chronic bronchitis or emphysema without airflow obstruction, shown by subsets 1,2,11, are not classified
as having COPD.
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4. Phenotypic intersection – Clinical, physiologic, and inflammatory
similarities and distinctions
4.1. Clinical – Asthma phenotypes and the 5th cluster
Moore and colleagues [7] categorized a large portion of the severe asthma research program
(SARP) population into 5 distinct phenotypic groups based upon cluster analysis (see Table
1). The 5th cluster had more fixed airways obstruction (non-normalizing) with little broncho‐
dilator responsivity, similar to the physiologic profile of a more classically defined COPD
patient. This type of phenotypic approach to asthma may better suit some refractory asthma
patients who require more tailored and individualized therapy [17-21].
Cluster 1 – 15% of
participants
Atopic, mostly younger females with onset of asthma in childhood, with normal lung function
and infrequent healthcare utilization or hospitalizations
Cluster 2 – 44% of
participants
Atopic, mostly females, mostly older adults, with onset of asthma in childhood, with normal
lung function and more asthma medication usage than cluster 1
Cluster 3 – 8% of
participants
Non-Atopic, mostly females over the age of 50 with onset of asthma in adulthood and obese
with body mass index >30, some decreased lung function, abundant asthma medication
usage and corticosteroid usage with the most healthcare utilization and hospitalizations that
appeared to be out of proportion to the degree of decreased lung function
Cluster 4 – 17% of
participants
Atopic, equal males and females with onset of asthma in childhood and the most severe
decline in lung function with most meeting a severe asthma definition and with only some
bronchodilator responsivity on lung function testing
Cluster 5 – 16% of
participants
Less Atopic, mostly females, with onset of asthma in childhood with most meeting a severe
asthma definition and with worst lung function of all clusters and little bronchodilator
responsivity
Table 1. Five Asthma Phenotypes Classified Using Cluster Analysis, adapted from [7].
4.2. Clinical – COPD phenotypes and the need for GOLD criteria revision in 2011
Not all COPD patients are alike. Some require oxygen and some do not. Some require one
maintenance inhaler whereas others require three. Some have 2 or more exacerbations per year
and some have few or no exacerbations. How can one account for these distinct differences in
patient presentation or phenotype?
Prior to 2011, the GOLD guidelines [9] categorized COPD severity based solely upon physio‐
logic criteria, especially the reduction in the FEV1. COPD patients are not always the same and
carry different risk factors for worsening lung function and exacerbations. These concepts, that
physiology does not adequately define groups of patients with similar therapeutic require‐
ments and not all COPD patients are the same, were addressed by creating new GOLD
classifications. In 2011, the use of level of lung dysfunction and airways obstruction continued,
but further categorization based upon clinical symptoms as well as healthcare utilization or
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risk were added to the classification scheme, as seen in Figure 1. Patients are classified into
four groups, A, B, C, and D based upon these three factors. Group A patients have better lung
function, fewer symptoms, and lower risk for hospitalization. Group B patients have better
lung function and lower risk for hospitalization but more symptoms; Group C patients have
more impaired lung function and higher risk but are less symptomatic; and Group D patients
have more impaired lung function, more symptoms, and greater risk for hospitalization. By
restructuring the classification system, COPD patients can now be seen as a range of potentially
diverse populations, with some patients not experiencing many symptoms or risk, whereas
other COPD patients have greater risk of exacerbations and symptoms and will be treated
more aggressively. In summary, the phenotypic differences between more symptomatic and/
or higher exacerbation risk coupled with physiologic function, are being used to not only
categorize COPD patients but also guide therapeutic management.
The current GOLD classification scheme has progressed significantly beyond the historical
labeling of patients with COPD as “pink puffers” or “blue bloaters.” These descriptions may
have addressed the physiologic differences between emphysema and chronic bronchitis
patients, but these phenotypic descriptions did not translate into standardized approaches for
medication usage or therapeutic management. The four phenotypes described in GOLD 2011
[9] now enable the patient’s care team to choose therapeutic options based on level of pulmo‐
nary physiologic function, risk of exacerbation/healthcare utilization, and level of symptoms.
Although still maintaining a stepped care approach, the use of phenotypic categories suggests
therapies directed at reducing specific needs manifested by individuals within each category.
The risk of exacerbations and significant lung function deterioration that can accompany them
are now targeted and higher risk patients could have more access to novel therapies such as
Phosphodiesterase-type 4 (PDE-4) inhibitors or chronic antibiotics like azithromycin as options
to reduce their risk of COPD exacerbations [22, 23].
4.3. Airways inflammation: Often different but present in both, and sometimes similar
amongst asthma & COPD
Both asthma and COPD are diseases of airway inflammation. In asthma, the inflammatory
cells and cytokines include CD4+T-helper cell lymphocytes, eosinophils, and IL 4,5,10, and 13
along with GM-CSF and TNF-alpha whereas in COPD, the inflammatory profile usually
consists of CD8+T-lymphocytes, neutrophils, and CD68+monocytes/macrophages [24]. Some
investigators have divided asthma into eosinophilic and non-eosinophilic categories [25]
emphasizing that non-eosinophilic asthma is a unique phenotype. Although there are signif‐
icant differences in the inflammatory components encountered in asthma and COPD [24, 26],
some asthmatics have a more neutrophil predominant inflammatory profile [27]. In contrast
with these differences in the inflammatory components of asthma and COPD, there are some
similar findings that occur in asthmatic and COPD patients who have fixed airways obstruc‐
tion. Jeffrey [28] notes that remodeling and inflammation occur in both asthma and COPD and
there are often major distinct differences in inflammation in the airways for COPD and asthma.
However, these differences are most apparent when “nonsmoking patients with asthma and
smokers with COPD from polar ends of the spectrum of “reversibility” (normalization) are
Asthma and COPD – Overlapping Disorders or Distinct Processes?
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compared” and as “disease becomes severe and the use of corticosteroids increases, the
patterns of inflammation become more similar, mainly because of increases of neutrophils in
both asthma and COPD”[28]. Further similarities in inflammatory patterns between asthma
and COPD include:
• Distinct subpopulations of individuals with COPD and chronic bronchitis have a thickened
reticular basement membrane (RBM) and bronchoalveolar lavage (BAL) eosinophilia that
are similar to what is seen in the chronic inflammatory changes of asthma [29]. The RBM is
thicker than normal in this subset of COPD patients who were smokers and showed
significant airflow reversibility after 14 days of oral steroid therapy [29]. RBM thickening is
usually considered a hallmark of severe asthma [30].
• The structural and inflammatory profiles observed in this subset of patients with COPD and
a thickened RBM and BAL eosinophilia make the distinction between asthma and COPD
less clear.
• Airway smooth muscle is increased both in COPD and asthma but the location of the smooth
muscle hypertrophy and enlargement may differ [31]. Airway smooth muscle enlargement
is also found in COPD but usually more in the smaller airways.
• The eosinophil has been a longstanding chronic inflammatory cell in asthma, whereas
eosinophils in COPD appear to be more active during acute exacerbations of COPD [24,
28]. It has been postulated that the slight increase of eosinophils encountered in stable COPD
perhaps do not degranulate [32].
As stated above there are stark contrasts in airway structure and inflammation in COPD and
asthma yet the question remains: why do striking similarities exist between the two as well?
As mentioned, the increase in airway smooth muscle mass that is observed ubiquitously in
asthmatics can be seen in COPD patients, and the eosinophil appears to be a critical inflam‐
matory cell in both diseases, albeit in COPD, its most significant role may be during acute
exacerbations. Furthermore, it is interesting to see that there are some COPD patients who
appear to have an inflammatory and airway structure profile that is more consistent with the
classic findings of asthma. Perhaps these findings explain why we see benefits of inhaled
steroids for some COPD patients. Compared with placebo, corticosteroids improve the
outcomes of COPD patients hospitalized for acute exacerbations and decrease readmission
rates [33]. In addition, the TORCH investigators [34] showed that inhaled corticosteroids
reduced exacerbation rates and improved the health status of COPD patients. The similarities
in airways inflammation and pathobiology seen in COPD and asthma may account for the
clinical improvements associated with inhaled corticosteroids in COPD patients. We now see
that the mainstay of therapy for asthma, inhaled corticosteroids, may improve outcomes in
COPD patients. That is, a medication historically reserved for asthmatics is now widely used
for COPD patients. Later in part 6 of this chapter, we will investigate this cross-treatment of
COPD and asthma further.
COPD Clinical Perspectives22
5. How can an asthmatic evolve to chronic obstruction indistinguishable
from COPD?
Airways remodeling in asthma can lead to more fixed, irreversible (non-normalizing) airways
obstruction [13, 35]. Airways remodeling is a series of events that include structural and
inflammatory changes that lead to fixed airways obstruction. Critical events in this pathway
include reticular basement membrane (RBM) thickening, airway smooth muscle (ASM)
hyperplasia and hyperreactivity, loss of ciliated epithelial cells, goblet cell (GC) hyperplasia
and increased mucous production, as well as fibroblast and myofibroblast activation [35].
When extensive airway remodeling occurs, asthmatics can appear clinically and physiologi‐
cally as if they had COPD with fixed, non-normalizing airways obstruction. Recent studies
suggest that airway remodeling and airway smooth muscle (ASM) hyperplasia and hypertro‐
phy occur at an early age, possibly even preceding the diagnosis of asthma and clinical
symptoms [31, 36]. These studies suggest that reticular basement membrane thickening can
occur even in childhood [37] and corroborate earlier investigations that showed that the lung
function decline in some asthmatics occurred early in childhood, and not progressively
throughout adulthood [38]. Thus, airway remodeling may precede both the clinical manifes‐
tations of asthma and the inflammation triggered by allergen exposure. The subsequent
inflammation intensifies the remodeling process and leads to fixed airways obstruction in early
adulthood. Thus, it seems plausible that the subset of asthma patients who have fixed
obstruction may have defects in ASM regulatory mechanisms and that ASM hyperplasia may
be an “early life event.”For these individuals, the inflammation and ensuing asthma accentu‐
ates basement membrane dysregulation and ultimately leads to fixed airways obstruction in
young asthma patients [31, 36-38].
6. Novel treatment paradigms: Asthma drugs treat COPD and vice-versa
According to current guidelines, inhaled corticosteroids (ICS) are the cornerstone and first line
therapy of persistent asthma while long acting beta (LABA) agonists and long acting anti-
muscarinic (LAMA) agents are first line therapy for COPD patients [9, 14, 15]. Despite this
paradigm of “inhaled steroids first in asthma and long acting bronchodilators first in COPD”,
inhaled corticosteroids can be helpful for some COPD patients and long acting bronchodilators
are commonly used as step up therapy in asthma when ICS therapy does not control symptoms
alone. In addition, systemic corticosteroids are beneficial for the treatment of exacerbations of
both diseases [9, 14, 15]. Recent investigations suggest that medications classically used for the
treatment of asthma may be beneficial for COPD and pharmacologic treatments usually used
for COPD may be advantageous in the management of some subpopulations of patients with
asthma.
6.1. Asthma and anti-inflammatory medications used for COPD
Recent studies show that inhaled corticosteroids, the mainstay of asthma pharmacotherapy,
improve multiple outcomes in individuals with COPD [9]. ICS can reduce the frequency of
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acute COPD exacerbations and improve respiratory health in patients with severe COPD [9,
34]. Although combined ICS and long acting beta agonist treatment slowed the reduction of
lung function in individuals with COPD in the TORCH trial, these results have not been
replicated in other trials [34, 39, 40]. However, as outlined in GOLD 2011 [9], inhaled cortico‐
steroids have a significant role in the management of COPD, particularly for those at high risk
for exacerbations and who are symptomatic despite long acting bronchodilator usage (GOLD
class C,D). The summary of evidence [9, 34, 39-43] supporting the role of inhaled corticoste‐
roids in the management of COPD includes the following:
• Long term treatment with inhaled steroids is recommended for patients with severe and
very severe airflow limitation and for patients with frequent exacerbations not controlled
by long acting bronchodilators.
• Inhaled steroids should be considered for GOLD class C and D patients.
• Long term monotherapy with inhaled steroids is not recommended in COPD as it is less
effective than a combination of LABA and ICS together.
The inflammation present in COPD, for at least some COPD patients, appears to be helped by
the addition of an inhaled steroid. Thus, historically labeled “asthma treatments” such as
inhaled steroids may be beneficial for patients with COPD. Additionally, anti-leukotriene
medications such as montelukast have shown some promise even in COPD patients as some
authors propose that the inflammation in COPD can be a target of leukotriene receptor
antagonist (LTRA) therapy. LTRA usage in elderly COPD patients appears to be safe and
efficacious and may improve outcomes in respiratory health in this population [44, 45].
6.2. COPD and long-acting inhaler medications used for asthma
Alternatively, treatments that were relegated historically as mainstay therapy for COPD have
also been used to treat asthma. Inhaled steroids are the principal treatment for persistent
asthma, but for more severe asthmatics, LABA’s are added to inhaled corticosteroids, similar
to adding an inhaled corticosteroid to a LABA for a more severe COPD patient. LABAs are
never used as monotherapy in asthma. However, combined LABA/ICS treatment is recom‐
mended for patients with severe asthma just as this combination is suggested therapy for
patients with more severe COPD.
Based upon many trials, multiple guidelines identify inhaled corticosteroids as the recom‐
mended first line treatment for asthma [14, 15, 46]. LABA inhalers are effective as step up
therapy, particularly in those asthmatics not controlled with inhaled corticosteroids alone [47,
48]. LABAs are indeed used in asthma; however, due to the risk of LABA monotherapy in
asthma [49], these agents are recommended only for step up therapy in those asthmatics not
controlled with an inhaled corticosteroid alone [14, 15]. Thus, LABAs can be used in both COPD
and asthma, although for COPD they are first line therapeutic options and for asthma they are
recommended only as add-on therapy choices in addition to inhaled corticosteroids. LABAs
are not first line therapy for asthma. Inhaled corticosteroid and LABA combination therapy is
recommended for both asthmatics and COPD patients with more severe disease [9, 14, 15].
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What about long acting muscarinic antagonist usage (LAMA) or long acting anticholinergic
(LAch) therapy in asthma? Recent studies show that treatment of severe asthmatics with a
LAMA can reduce exacerbations and improve airflow obstruction [50]. In patients with asthma
that is inadequately controlled with ICS, addition of a LAMA improves lung function and
symptoms and is equivalent to the addition of a LABA [51]. Caution, however, has been
advised by some authors including Bel [52], stating that the use of LAMAs and antimuscarinic
agents may best be reserved for those asthma patients who have fixed airflow obstruction as
evidenced by baseline FEV1/FVC ratios of <0.70.
Table 2 describes and summarizes some of these trials which have shown cross-therapy choices
for asthma and COPD.
Trial & Reference Medications Used/Disease Summary of Meaningful Findings
TALC [51] LAMA (tiotropium) use in
asthma
Tiotopium as effective as long acting bronchodilator for
uncontrolled asthmatics
Tiotropium added to asthmatics
poorly controlled on LABA/ICS
[50]
LAMA (tiotropium) use in
asthma
LAMA use decreased exacerbations in severe asthmatics
and showed minimal improvement in FEV1
Long-term montelukast in
moderate to severe COPD [44,
45]
LTRA use in COPD LTRA use appears safe and efficacious and may improve
respiratory symptom control and exacerbations,
particularly for elderly moderate to severe COPD patients
Meta-Analyses for ICS usage in
more severe COPD or COPD with
higher risk of exacerbations
[41-43]
ICS for COPD ICS reduce the risk of exacerbations, with an emphasis
placed on more severe COPD patients
TORCH [34] ICS for COPD ICS therapy decreases exacerbations and modestly slows
the progression of respiratory symptoms in COPD;
possible or minimal impact found on lung function and
mortality somewhat unique to TORCH trial.
UPLIFT [53] Triple Therapy with LAMA,
LABA and ICS for COPD
patients
Suggests additive benefit to triple inhaler therapy for
more advanced COPD patients
Abbreviations: LTRA-leukotriene receptor antagonist, LAMA-long acting muscarinic antagonist, LABA-long acting beta
agonist, ICS-inhaled corticosteroid, FEV1-forced expiratory volume in 1 second, COPD-chronic obstructive pulmonary
disease
Table 2. Summary of Novel Approaches Where Cross-Disease Therapeutic Options Have Shown Benefit.
7. Conclusion
We began this chapter with the question: are asthma and COPD completely distinct diseases
or is there some degree of overlap? In response, we conclude that they are separate entities
that are treated and approached in unique ways for the most part; however, for subpopulations
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of individuals with asthma or COPD, there is considerable clinical, physiologic, and inflam‐
matory profile overlap. These disorders are syndromes defined by constellations of clinical,
historical, physical examination, physiological, and inflammatory features. Recent investiga‐
tions suggest that there are numerous subcategories of asthma and COPD and that some of
these subcategories may have significant similarities.
Thus, COPD and asthma may coexist or overlap in individual patients or within specific
phenotypic categories. Both diseases are characterized by airways inflammation and some‐
times cannot be distinguished clinically. The physiologic differences between asthma and
COPD are further confused by ambiguous use of reversibility to mean either responsiveness
to bronchodilators or normalization of lung function. Historically, asthma has been associated
with AFL that normalizes and returns to predicted levels with therapy whereas, in COPD, lung
function progressively declines and no treatment has been shown to return it to predicted
levels. However, there is a subpopulation of asthmatics that develop fixed AFL and despite
treatment do not exhibit normalization of lung function.
Although the inflammatory profiles of asthma and COPD are traditionally considered to be
distinct, more recent investigations and phenotypic categorizations suggest that there are
populations of asthmatics with inflammatory profiles that are suggestive of COPD and some
groups of patients with COPD may have inflammatory profiles that resemble those seen in
asthma.
Although the principal guidelines for management of COPD and asthma are very different,
considerable overlap in treatments does occur. Recent studies demonstrate that medications
such as LAMAs that are traditionally used only for the treatment of COPD may be beneficial
in patients with asthma and other drugs such as LTRAs that are usually only used for the
treatment of asthma may be effective in patients with COPD. But, for most individuals with
COPD or asthma, the initial treatment for COPD begins with maintenance long acting
bronchodilators and for asthma with maintenance inhaled corticosteroids. Therefore, we feel
that asthma and COPD can usually be addressed as separate entities but there are numerous
times where the diseases and their treatments overlap.
In conclusion, it may be appropriate to approach some COPD patients as if they were more
asthmatic, and some asthmatics as if they were more like COPD. The Dutch hypothesis
suggesting that asthma and COPD may have common pathogenetic mechanisms is undergo‐
ing a resurgence as phenotypically distinct subpopulations of individuals with COPD and
asthma are being identified. Although most of these subpopulations are distinct, some share
similar clinical, physiologic, and inflammatory profiles. Finally, the therapeutic distinctions
between asthma and COPD are blurring as medications traditionally used for one disorder are
shown to be beneficial for the other. Ultimately, the goal is to develop therapeutic guidelines
based upon a patient’s phenotypic profile. As phenotypes become more descriptive, it may
prove beneficial to categorize patients as “chronic obstructive asthma with fixed obstruction”,
or “COPD with asthmatic/more prominent eosinophilic airways inflammatory features”, or
“COPD with an allergic inflammatory component” to discern which COPD patients might
benefit from inhaled corticosteroids or which asthmatics might improve with antimuscarinic
bronchodilators.
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